Efficacy and safety of tezepelumab in Japanese patients with chronic rhinosinusitis with nasal polyps: A subpopulation analysis of the randomized WAYPOINT study.
OBJECTIVE Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, effectively reduced polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab also reduced the need for nasal polyp surgery and systemic corticosteroids (SCS) in the phase 3 WAYPOINT study across 10 countri...